scholarly article | Q13442814 |
meta-analysis | Q815382 |
P356 | DOI | 10.1002/14651858.CD011460.PUB2 |
P8608 | Fatcat ID | release_qamjaohtcjesfgibdg6yyv2iju |
P932 | PMC publication ID | 6483480 |
P698 | PubMed publication ID | 26403220 |
P50 | author | Sheena Derry | Q28036347 |
Philip J Wiffen | Q28036553 | ||
Rae Jean Proeschold-Bell | Q90073384 | ||
Katrien Naessens | Q117285414 | ||
P2860 | cites work | Tapentadol for chronic musculoskeletal pain in adults | Q24187807 |
Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain | Q24194524 | ||
Impact of covert duplicate publication on meta-analysis: a case study | Q24685600 | ||
Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome | Q26826917 | ||
Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects | Q29619558 | ||
The number needed to treat: a clinically useful measure of treatment effect | Q29619672 | ||
Meta-analysis in clinical research | Q29620885 | ||
Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice | Q33566361 | ||
Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release | Q33775071 | ||
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations | Q37022616 | ||
Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain | Q37352277 | ||
The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol | Q38191866 | ||
Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain | Q38446521 | ||
The pharmacologic management of cancer pain | Q80238545 | ||
Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain | Q87855756 | ||
Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain | Q95451268 | ||
P433 | issue | 9 | |
P921 | main subject | tapentadol | Q414463 |
cancer pain | Q3712728 | ||
P304 | page(s) | CD011460 | |
P577 | publication date | 2015-09-25 | |
P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
P1476 | title | Oral tapentadol for cancer pain |
Q57498749 | Cancer Pain Management: Opioid Analgesics, Part 2 |
Q43075660 | High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews. |
Q98892340 | Indian Society for Study of Pain, Cancer Pain Special Interest Group Guidelines on Pharmacological Management of Cancer Pain (Part I) |
Q39144886 | Multidimensional Treatment of Cancer Pain |
Q60935032 | Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study |
Q39153206 | Opioids for cancer pain - an overview of Cochrane reviews. |
Q38682609 | Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. |
Q94333994 | Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults |
Q94333686 | Oral paracetamol (acetaminophen) for cancer pain |
Q38682606 | Oral paracetamol (acetaminophen) for cancer pain. |
Q55023336 | Spontaneously reported adverse drug events related to tapentadol and oxycodone/naloxone in Australia. |
Q24187807 | Tapentadol for chronic musculoskeletal pain in adults |
Q64981989 | Tapentadol in the management of cancer pain: current evidence and future perspectives. |
Q38782574 | Tramadol with or without paracetamol (acetaminophen) for cancer pain. |
Q88271159 | Understanding osteoporotic pain and its pharmacological treatment |
Q50048496 | Updates in palliative care - overview and recent advancements in the pharmacological management of cancer pain. |
Search more.